The Lancet Haematology

Published by: Elsevier Science, Inc.  

People

  1. Giralt
    Giralt
  2. Matasar
    Matasar
  3. Noy
    Noy
  4. Abdel-Wahab
    Abdel-Wahab
  5. Dogan
    Dogan
  6. Hassoun
    Hassoun
  7. Horwitz
    Horwitz
  8. Landau
    Landau
  9. Palomba
    Palomba
  10. Rampal
    Rampal

Groups

  1. Department of Medicine (26)
  2. Hematologic Malignancies, Division of (24)
  3. Center for Hematologic Malignancies (23)
  4. Lymphoma (12)
  5. Survivorship Research (7)
  6. Bone Marrow Transplant (6)
  7. Population Sciences Research Program (6)
  8. Adult Leukemia (5)
  9. Executive Committee, Center for Hematologic Malignancies (5)
  10. Biostatistics Service (4)
Search Within
Formats
  1. Journal Article (24)
  2. Review (6)
  3. Editorial (3)
  4. Correspondence (1)
Groups
  1. Department of Medicine (26)
  2. Hematologic Malignancies, Division of (24)
  3. Center for Hematologic Malignancies (23)
  4. Lymphoma (12)
  5. Survivorship Research (7)
  6. Bone Marrow Transplant (6)

More Groups

People
  1. Eytan Stein (4)
  2. Martin Tallman (4)
  3. Sergio Giralt (4)
  4. Anas Younes (3)
  5. Ariela Noy (3)
  6. Matthew Matasar (3)

More People

Years
  1. 2022 (3)
  2. 2021 (10)
  3. 2020 (10)
  4. 2019 (4)
  5. 2018 (3)
  6. 2017 (3)

More Years

Publishers
  1. Elsevier Science, Inc. (34)

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Malignancy-associated haemophagocytic lymphohistiocytosis
    Review

    Setiadi, A.; Zoref-Lorenz, A.; Lee, C. Y.; Jordan, M. B.; Chen, L. Y. C.
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
    Review

    Thanarajasingam, G.; Minasian, L. M.; Bhatnagar, V.; Cavalli, F.; De Claro, R. A.; Dueck, A. C.; El-Galaly, T. C.; Everest, N.; Geissler, J.; Gisselbrecht, C.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): A single-arm, phase 2 clinical trial
    Journal Article

    Admiraal, R.; Nierkens, S.; Bierings, M. B.; Bredius, R. G. M.; van Vliet, I.; Jiang, Y.; Lopez-Yurda, M.; Versluijs, A. B.; Zwaan, C. M.; Lindemans, C. A.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
    Review

    Kantarjian, H.; Short, N. J.; DiNardo, C.; Stein, E. M.; Daver, N.; Perl, A. E.; Wang, E. S.; Wei, A.; Tallman, M.
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Blunted humoral response after mRNA vaccine in patients with haematological malignancies
    Editorial

    Kamboj, M.
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
    Journal Article

    Straus, D. J.; Długosz-Danecka, M.; Connors, J. M.; Alekseev, S.; Illés, Á; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study
    Journal Article

    Sharma, A.; Bhatt, N. S.; St Martin, A.; Abid, M. B.; Bloomquist, J.; Chemaly, R. F.; Dandoy, C.; Gauthier, J.; Gowda, L.; Perales, M. A.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save

    • The Lancet Haematology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Haematology 2352-3026 Unknown
    Lancet Haematology 2352-3026 Elsevier Science, Inc.
    Lancet Haematology 2352-3026 Elsevier Science, Inc.
    The Lancet Haematology 2352-3026 Elsevier Inc.
    The Lancet Haematology 23523026 Unknown
    The Lancet Haematology 23523026 Elsevier Inc.
    The Lancet Haematology 23523026 Elsevier L D
    The Lancet Haematology 2352-3026 Elsevier Science, Inc.
    The Lancet Haematology 2352-3026 Elsevier Inc.